South & Central America Molecular Diagnostics for Infectious Disease Market Forecast to 2030
South & Central America Molecular Diagnostics for Infectious Disease Market Forecast to 2030 – Regional Analysis – by Type (Point-of-Care Testing and Laboratory Testing), End User [Point-of-Care Testing (Human Testing and Vet Testing) and Laboratory Testing (Human Testing and Vet Testing)], Application [Point-of-Care Testing (Detection of Single Pathogen, Detection of Two or More Pathogens, Evaluation of Emerging Novel Infections, Surveillance and Early Detection of Biothreat Agents and Diseases-Related Biomarker, and Antimicrobial Resistance Profiling) and Laboratory Testing (Patient stratification, Drug Regimen Selection, Toxicity Avoidance, Therapeutic Monitoring, and Detection of Predisposition to Disease)], Disease Type [Point-of-Care Testing (Sepsis, Prosthetic Joint Infection (PJI), Endocarditis, STDs, Mononucleosis, Group A Streptococcus (GAS), and Others) and Laboratory Testing (Sepsis, Prosthetic Joint Infection (PJI), Endocarditis, STDs, Chlamydia, Gastrointestinal Infection, Tuberculosis, H1N1 Virus, and Others)], Infection Type [Point-of-Care Testing (Bacteria, Viral, Fungi, and Others) and Laboratory Testing (Bacteria, Viral, Fungi, and Others)]
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Advancements in Molecular Diagnostics Technologies Fuels the South & Central America Molecular Diagnostics for Infectious Disease Market
Genetic and genomic research has led to the development of molecular diagnostic techniques that focus on nucleic acid detection, which provide new methods for detecting infectious diseases with a fast turnaround time. A molecular diagnostic technique detects multiple pathogens and analyzes drug-resistant genes of pathogens and pathogen homology analysis, making it an increasingly important tool for the early diagnosis of infectious diseases. Molecular diagnostic techniques and platforms are used in all areas of anatomic and clinical pathologies. DNA or RNA sequences associated with disease, including single nucleotide polymorphism, deletions, rearrangements, and insertions, can be detected via molecular diagnostic tests. Conventionally, CT scans, hematological tests, and reverse transcription-PCR (RT-PCR) were used for testing. Due to growing infectious diseases, the need for rapid, precise testing platforms surged to overcome the disadvantages of conventional testing. Computed tomography (CT), a cost-intensive procedure that may not be available in all hospitals, fails to detect viral infections and other diseases in asymptomatic patients. RT-PCR was also time-consuming and could not detect a low viral load during the early stages of infection. Reverse transcription loop-mediated isothermal amplification (RT-LAMP), microarray-based detection, aptamer-based diagnosis, SHERLOCK, SHERLOCKv2, FET Biosensors, cell-based potentiometric diagnosis, and molecular imprinting technology are a few examples of novel molecular diagnostics techniques developed for infectious disease diagnosis. In the last few years, the FDA reports have indicated that molecular testing, antigen-dependent testing, and serological testing have been approved due to the advancements. Collaborative efforts by scientific communities in different countries to manage infectious diseases and reduce the extent of mortality have benefited the overall molecular tools and diagnosis landscape, which will likely create significant opportunities for the molecular diagnostics for infectious diseases market in the future.
South & Central America Molecular Diagnostics for Infectious Disease Market Overview
The molecular diagnostics for infectious disease market in South & Central America is segmented into Argentina, Brazil, and the Rest of South & Central America. The market growth in the region is attributed to the aging population and initiatives by major players in the medical device industry. Furthermore, the prevalence of infectious diseases that demand promising diagnostic test options contributes to the market growth in the region. According to UN AIDS Organization, ~960,000 people were living with HIV in Brazil in 2021. The World Data Atlas stated that the prevalence of HIV has increased from 0.5% in 2002 to 0.6% in 2021, with an average annual growth rate of 4.12%. As a result, Brazil is focusing on introducing self-testing kits through private and public health services or pharmacies. The increasing number of cases of tuberculosis in Brazil is also responsible for the growth of the molecular diagnostics for infectious diseases market. According to World Data Atlas, the incidence rate of tuberculosis in Brazil rose from 43 cases per 100,000 people in 2014 to 48 cases per 100,000 people in 2021. The WHO recommended the use of molecular NAAT tests for TB detection instead of smear microscopy, as the former can detect TB more accurately. Moreover, some of these WHO-endorsed tests can detect mycobacterial gene mutations associated with anti-TB drug resistance, allowing clinicians to tailor effective TB treatment. Countries in South & Central America are improving their healthcare infrastructure by allowing new market players to enter the business. In addition, they are investing and taking interest in improving their healthcare research capabilities, and focusing on adopting advanced therapies and diagnostics for various infectious diseases. Thus, the shift in focus toward having a modern and more accessible healthcare system is expected to benefit the market for infectious diagnostics and therapeutics in South & Central America in the coming years.
South & Central America Molecular Diagnostics for Infectious Disease Market Revenue and Forecast to 2030 (US$ Million)
South & Central America Molecular Diagnostics for Infectious Disease Market Segmentation
The South & Central America molecular diagnostics for infectious disease market is segmented based on type, end user, application, disease type, infection type, and country.
Based on type, the South & Central America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held a larger South & Central America molecular diagnostics market for infectious disease market share in 2022.
The South & Central America molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held a larger South & Central America molecular diagnostics market for infectious disease market share in 2022. Additionally, the human testing segment, by laboratory testing, held a larger South & Central America molecular diagnostics market for infectious disease market share in 2022.
Based on application, the South & Central America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held the largest South & Central America molecular diagnostics for infectious disease market share in 2022. Additionally, the drug regimen selection segment, by laboratory testing, held the largest South & Central America molecular diagnostics for infectious disease market share in 2022.
Based on disease type, the South & Central America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held the largest South & Central America molecular diagnostics for infectious disease market share in 2022. Additionally, the STDs segment, by laboratory testing, held the largest South & Central America molecular diagnostics for infectious disease market share in 2022.
Based on infection type, the South & Central America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held the largest South & Central America molecular diagnostics for infectious disease market share in 2022. Additionally, the bacteria segment, by laboratory testing, held the largest South & Central America molecular diagnostics for infectious disease market share in 2022.
Based on country, the South & Central America molecular diagnostics for infectious disease market is categorized into Brazil and the Rest of South & Central America. The Rest of South & Central America dominated the South & Central America molecular diagnostics for infectious disease market in 2022.
F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc, bioMerieux SA, Danaher Corp, Hologic Inc, Siemens Healthineers AG, Bruker Corp, and DiaSorin SpA are some of the leading companies operating in the South & Central America molecular diagnostics for infectious disease market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the Research Team’ research, the South & Central America molecular diagnostics for infectious disease market was valued at US$ 223.01 million in 2022 and is expected to reach US$ 584.80 million by 2030, registering a CAGR of 12.8% from 2022 to 2030. Molecular diagnostics for infectious diseases in personalized medicine and surging prevalence of infectious disease globally are among the critical factors attributed to the South & Central America molecular diagnostics for infectious disease market expansion.
Genome research has become more convenient and cost-effective with progress in high-throughput techniques. Molecular diagnostics is becoming increasingly indispensable in clinical laboratories as these kits and tests provide rapid detection results as opposed to conventional tests, which involve culturing microbes in laboratory conditions in a few cases. Medical treatments and interventions are tailored to each patient using precision medicine based on their unique genetic makeup, lifestyle, and environment. Molecular diagnostics plays an important role in this approach, as it enables the identification of specific biomarkers, genetic mutations, and gene expression patterns that impact decision-making related to the treatment of patients. Drug development has become increasingly dependent on molecular diagnostics. Various molecular imaging techniques are used in screening, detecting, diagnosing, treating, and assessing heterogeneity to make progression plans, examine molecular characteristics, and monitor patient outcomes. Personalized medicine generally aims to interrogate the genomic information of a patient, e.g., drug metabolism polymorphisms help guide drug choice and dosage. In infectious diseases, personalized medicine concepts can be used to rapidly identify disease-causing microorganisms, determine their antimicrobial resistance profiles, and ascertain an appropriate antimicrobial treatment for the proper management of the patient based on the results. Point-of-care testing for infectious diseases requires the acceptance of medical authorities, development of new technology and communication platforms, and reimbursement policies so that the greatest number of patients can benefit from lifesaving and time-saving procedures. Introducing these techniques into clinical practice would enable the identification of molecular targets in each patient, along with facilitating the tracking of the molecular progression of diseases.
Thus, with ever-evolving technology, the market for molecular diagnostics for infectious diseases seems to have a bright future.
On the contrary, Limitations associated with molecular testing hampers the growth South & Central America molecular diagnostics for infectious disease market.
Based on type, the South & Central America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held 56.7% share of South & Central America molecular diagnostics for infectious disease market in 2022, amassing US$ 126.42 million. It is projected to garner US$ 319.86 million by 2030 to expand at 12.3% CAGR during 2022-2030.
The South & Central America molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held 96.5% share of the South & Central America molecular diagnostics for infectious disease market in 2022, amassing US$ 93.23 million. It is projected to garner US$ 254.25 million by 2030 to expand at 13.4% CAGR during 2022-2030. Additionally, the human testing segment, by laboratory testing, held 96.1% share of the South & Central America molecular diagnostics for infectious disease market in 2022, amassing US$ 121.49 million. It is projected to garner US$ 305.63 million by 2030 to expand at 12.2% CAGR during 2022-2030.
Based on application, the South & Central America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held 43.8% share of the South & Central America molecular diagnostics for infectious disease market in 2022, amassing US$ 42.26 million. It is projected to garner US$ 113.81 million by 2030 to expand at 13.2% CAGR during 2022-2030. Additionally, the drug regimen selection segment, by laboratory testing, held 32.9% share of the South & Central America molecular diagnostics for infectious disease market in 2022, amassing US$ 41.54 million. It is projected to garner US$ 102.82 million by 2030 to expand at 12.0% CAGR during 2022-2030.
Based on disease type, the South & Central America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held 57.6% share of the South & Central America molecular diagnostics for infectious disease market in 2022, amassing US$ 55.68 million. It is projected to garner US$ 153.35 million by 2030 to expand at 13.5% CAGR during 2022-2030. Additionally, the STDs segment, by laboratory testing, held 40.6% share of the South & Central America molecular diagnostics for infectious disease market in 2022, amassing US$ 51.28 million. It is projected to garner US$ 135.86 million by 2030 to expand at 13.0% CAGR during 2022-2030.
Based on infection type, the South & Central America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held 48.7% share of the South & Central America molecular diagnostics for infectious disease market in 2022, amassing US$ 47.01 million. It is projected to garner US$ 126.21 million by 2030 to expand at 13.1% CAGR during 2022-2030. Additionally, the bacteria segment, by laboratory testing, held 48.4% share of the South & Central America molecular diagnostics for infectious disease market in 2022, amassing US$ 61.21 million. It is projected to garner US$ 151.55 million by 2030 to expand at 12.0% CAGR during 2022-2030.
Based on country, the South & Central America molecular diagnostics for infectious disease market is categorized into Brazil and the Rest of South & Central America. The Rest of South & Central America held 66.3% share of South & Central America molecular diagnostics for infectious disease market in 2022, amassing US$ 147.92 million. It is projected to garner US$ 382.75 million by 2030 to expand at 12.6% CAGR during 2022-2030.
Key players operating in the South & Central America molecular diagnostics for infectious disease market are F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc, bioMerieux SA, Danaher Corp, Hologic Inc, Siemens Healthineers AG, Bruker Corp, and DiaSorin SpA, among others.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the South & Central America molecular diagnostics for infectious disease market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the molecular diagnostics for infectious disease market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 South & Central America Molecular Diagnostic for Infectious Diseases Market, by Country, Market attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Molecular Diagnostic for Infectious Diseases Market – Key Industry Dynamics
4.1 Market Drivers:
4.1.1 Surging Prevalence of Infectious Disease Globally
4.1.2 Rising Application of Molecular Diagnostics in Veterinary Infectious Diseases
4.2 Market Restraints
4.2.1 Limitations Associated with Molecular Testing
4.3 Market Opportunities
4.3.1 Advancements in Molecular Diagnostics Technologies
4.4 Future Trends
4.4.1 Molecular Diagnostics for Infectious Diseases in Personalized Medicine
4.5 Impact Analysis:
5. Molecular Diagnostic for Infectious Diseases Market – South & Central America Market Analysis
5.1 South & Central America Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 – 2030
6. South & Central America Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Type
6.1 Overview
6.2 South & Central America Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
6.3 Point-of-Care Testing
6.3.1 Overview
6.3.2 Point-of-Care Testing: South & Central America Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Laboratory Testing
6.4.1 Overview
6.4.2 Laboratory Testing: South & Central America Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
7. South & Central America Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by End User
7.1 Overview
7.2 South & Central America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
7.2.1 South & Central America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
7.2.2 South & Central America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
8. South & Central America Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Application
8.1 Overview
8.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
8.3 Point-of-Care Testing
8.3.1 Overview
8.3.2 South & Central America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
8.4 Laboratory Testing
8.4.1 Overview
8.4.2 South & Central America: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
9. South & Central America Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Disease Type
9.1 Overview
9.2 South & Central America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
9.3 Point-of-Care Testing
9.3.1 Overview
9.3.2 South & Central America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
9.3.2.1 South & Central America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
9.4 Laboratory Testing
9.4.1 Overview
9.4.2 South & Central America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
9.4.2.1 South & Central America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
10. South & Central America Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Infection Type
10.1 Overview
10.2 South & Central America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
10.3 Point-of-Care Testing
10.3.1 Overview
10.3.2 South & Central America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
10.4 Laboratory Testing
10.4.1 Overview
10.4.2 South & Central America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
11. South & Central America Molecular Diagnostic for Infectious Diseases Market – Country Analysis
11.1 South & Central America Molecular Diagnostic for Infectious Diseases Market, Revenue and Forecast to 2030
11.1.1 South & Central America Molecular Diagnostic for Infectious Diseases Market, by Country
11.1.1.1 Brazil
11.1.1.1.1 Brazil Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.1.2 Brazil: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
11.1.1.1.3 Brazil: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
11.1.1.1.4 Brazil: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
11.1.1.1.5 Brazil: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
11.1.1.1.6 Brazil: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
11.1.1.1.7 Brazil: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
11.1.1.1.7.1 Brazil: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
11.1.1.1.8 Brazil: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
11.1.1.1.8.1 Brazil: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
11.1.1.1.9 Brazil: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
11.1.1.1.10 Brazil: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
11.1.1.2 Rest of South & Central America
11.1.1.2.1 Rest of South & Central America Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.2.2 Rest of South & Central America: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
11.1.1.2.3 Rest of South & Central America: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
11.1.1.2.4 Rest of South & Central America: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
11.1.1.2.5 Rest of South & Central America: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
11.1.1.2.6 Rest of South & Central America: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
11.1.1.2.7 Rest of South & Central America: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
11.1.1.2.7.1 Rest of South & Central America: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
11.1.1.2.8 Rest of South & Central America: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
11.1.1.2.8.1 Rest of South & Central America: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
11.1.1.2.9 Rest of South & Central America: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
11.1.1.2.10 Rest of South & Central America: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
12. Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market, (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 F. Hoffmann-La Roche Ltd
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Abbott Laboratories
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Thermo Fisher Scientific Inc
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 bioMerieux SA
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Danaher Corp
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Hologic Inc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Siemens Healthineers AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Bruker Corp
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 DiaSorin SpA
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
14. Appendix
14.1 About Us
14.2 Glossary of Terms
LIST OF TABLES
Table 1. South & Central America Molecular Diagnostic for Infectious Diseases Market Segmentation
Table 2. South & Central America Molecular Diagnostic for Infectious Diseases Market, for Point of Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 3. South & Central America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 4. South & Central America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 5. South & Central America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 6. South & Central America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 7. South & Central America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 8. South & Central America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 9. South & Central America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 10. South & Central America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 11. South & Central America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 12. Brazil Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 13. Brazil Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 14. Brazil Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 15. Brazil Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 16. Brazil Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 17. Brazil Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 18. Brazil Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 19. Brazil Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 20. Brazil Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 21. Brazil Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 22. Brazil Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 23. Rest of South & Central America Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 24. Rest of South & Central America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 25. Rest of South & Central America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 26. Rest of South & Central America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 27. Rest of South & Central America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 28. Rest of South & Central America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 29. Rest of South & Central America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 30. Rest of South & Central America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 31. Rest of South & Central America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 32. Rest of South & Central America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 33. Rest of South & Central America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 34. Organic Developments Done By Companies
Table 35. Inorganic Developments Done By Companies
Table 36. Glossary of Terms, Molecular Diagnostic for Infectious Diseases Market
LIST OF FIGURES
Figure 1. South & Central America Molecular Diagnostic for Infectious Diseases Market Segmentation, By Country
Figure 2. South & Central America Molecular Diagnostic for Infectious Diseases Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. South & Central America Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 – 2030
Figure 5. South & Central America Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
Figure 6. Point-of-Testing: South & Central America Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Laboratory Testing: South & Central America Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. South & Central America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
Figure 9. Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
Figure 10. South & Central America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
Figure 11. South & Central America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
Figure 12. South & Central America Molecular Diagnostic for Infectious Diseases Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 13. South & Central America Molecular Diagnostic for Infectious Diseases Market, By Key Countries, 2022 and 2030 (%)
Figure 14. Brazil Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 15. Rest of South & Central America Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 16. Growth Strategies Done by the Companies in the Market, (%)
The List of Companies – South & Central America Molecular Diagnostics for Infectious Disease Market
1. F. Hoffmann-La Roche Ltd
2. Abbott Laboratories
3. Thermo Fisher Scientific Inc
4. bioMerieux SA
5. Danaher Corp
6. Hologic Inc
7. Siemens Healthineers AG
8. Bruker Corp
9. DiaSorin SpA
You must be logged in to post a review.
Reviews
There are no reviews yet.